News
These ETFs can handle volatile markets.
Via The Motley Fool · March 22, 2026
XRP will have a hard time repeating its past success.
Via The Motley Fool · March 22, 2026
The key to understanding Bitcoin is the four-year cycle.
Via The Motley Fool · March 22, 2026
Semiconductor stocks have soared over the past couple of years. The rally doesn't look like it's over yet.
Via The Motley Fool · March 22, 2026
Amid escalating tensions in the Middle East, a rare scene has emerged in the cryptocurrency market: institutions bought $1.06 billion in Bitcoin ETFs in a single week, while retail investors were taking short positions. In this game of hedging versus speculation, how should ordinary investors position themselves?
Via GlobePRwire · March 22, 2026
We live in interesting times, and these assets are built for exactly that.
Via The Motley Fool · March 22, 2026
The current "buy low" opportunity and returning leadership from tech stocks make the S&P 500 a compelling buy.
Via The Motley Fool · March 22, 2026
Pepeto's latest presale stage sold out before its deadline after the team shipped a bridge upgrade that removes gas fees
Via First Publisher · March 21, 2026
AI stocks have had a bad 2026 so far.
Via The Motley Fool · March 21, 2026

This global beverage company had a strong run in 2025, and now, its stock is set to join one of the top funds in the market.
Via The Motley Fool · March 21, 2026
This S&P 500 ETF is low-cost and great for beginner investors.
Via The Motley Fool · March 21, 2026
There's good news and bad news for investors right now.
Via The Motley Fool · March 21, 2026
A former Binance executive inside the Ethereum based crypto Pepeto's team just moved the exchange tools into their last testing
Via First Publisher · March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
Via The Motley Fool · March 21, 2026
The Pepeto team just completed a full security upgrade on its DeFi exchange and presale capital responded within hours. Funds
Via First Publisher · March 21, 2026
Pepeto just crossed $8.24 million in presale and every metric is flashing the same signal the market produced right before
Via First Publisher · March 21, 2026
The soaring price of energy and geopolitical instability means energy stocks are an essential part of an investor's portfolio.
Via The Motley Fool · March 21, 2026
Investors want what they want, and this fund gives it to them.
Via The Motley Fool · March 21, 2026
The war will likely continue to roil markets.
Via The Motley Fool · March 21, 2026

Explore how differing costs, yields, and global exposure set these two real estate ETFs apart for income and diversification seekers.
Via The Motley Fool · March 21, 2026
Emerging markets stocks are carrying last year's momentum into 2026, and the Schwab Fundamental Emerging Markets Equity ETF is benefiting.
Via The Motley Fool · March 21, 2026
Here are some things you should not do in a TFSA to stay on the CRA's good side.
Via The Motley Fool · March 21, 2026
All it takes is time and consistency.
Via The Motley Fool · March 21, 2026
YieldMax just launched an ETF designed to double the distribution yield of the Schwab U.S. Dividend Equity ETF. But there are trade-offs.
Via The Motley Fool · March 21, 2026
Senator John Boozman's XTWO ETF purchase highlights a shift to 2-year duration as investors seek yield amid unclear Fed policy outlook, says BondBloxx.
Via Benzinga · March 21, 2026